Advertisement

Topics

Increasing Optionality For Licensors, Rise Of Small-Cap Partners Ongoing

11:57 EDT 3 Jul 2017 | SCRIP

Companies with market caps below $1bn continue to represent a growing percentage of biopharma deal-making, giving firms looking to license...

      

Related Stories

 

Original Article: Increasing Optionality For Licensors, Rise Of Small-Cap Partners Ongoing

NEXT ARTICLE

More From BioPortfolio on "Increasing Optionality For Licensors, Rise Of Small-Cap Partners Ongoing"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...